The METER international, retrospective chart review study was performed to gain insight into how clinicians apply myelofibrosis treatment today and assess its effectiveness.
Advertisement
Advertisement
Mark Sorial, PharmD, BCOP, shared the latest research from the Salvia Jain Lab's PETAL Consortium.
Bexobrutideg, an orally bioavailable, brain-penetrant BTK degrader, is being evaluated in a phase 1a/b study.
This agent which has newly received an ODD for MDS recalibrates the immune system to attack hematological and solid tumors.
Machine learning may aid point-of-care clinical decision-making for NHL patients receiving CAR T-cell therapy.
Some major themes for practice include identifying patients at risk for early progression and emphasis on quality of life.
Advertisement
Advertisement
Editorial Board
Mehdi Hamadani, MDProfessor of Medicine in the Division of Hematology and Oncology at the Medical College of Wisconsin
Krina Patel, MD, MScAssociate Professor in the Department of Lymphoma and Myeloma at MD Anderson Cancer Center
Naval Daver, MDAssociate Professor in the Department of Leukemia at MD Anderson Cancer Center
Uma Borate, MBBSAssociate Professor in the Division of Hematology at The Ohio State University
Rahul Banerjee, MD, FACPAssistant Professor, Division of Hematology and Oncology, University of Washington
Hira Mian, MD, MSc, FRCPCAssociate Professor in the Department of Oncology at McMaster University
Podcasts
Dr. Usmani, of the Memorial Sloan Kettering Cancer Center, highlights multiple myeloma news from the SOHO 2024 conference.
Dr. Venugopal, of the Sylvester Comprehensive Cancer Center, shares MDS updates from the SOHO 2024 meeting.
Dr. Daver highlights AML news from the Twelfth Annual Meeting of the Society of Hematologic Oncology.
Dr. Shadman, of the Fred Hutchinson Cancer Center, shares CLL news from the SOHO 2024 Annual Meeting.
Dr. Bose highlights news on MPN featured at the SOHO 2024 Annual Meeting.
Dr. Osman discusses classification and treatment approaches for patients with high-risk MDS.
Rami Komrokji, MD, describes incorporation of molecular data, tailoring treatment by disease risk, and new therapies in MDS.
Dr. Hilal covers the debates surrounding MRD, whether he uses MRD to make treatment decisions, and more.
Video Insights
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Knowledge Hubs
Trending on MashupMD
Nature
Extended Look Into Long-Term Zoledronic Acid in Multiple Myeloma
ManniMD1
ManniMD1Manni Mohyuddin, MD, covers new data suggesting that
#myeloma #mmsm
American Society of Hematology
Two NK Receptor Ligands Control T-cell Targeting of AML Cells
BloodJournal
BloodJournalStudy finds two NK receptor ligands, PVR and B7-H6,
#immunobiologyandimmunotherapy
#myeloidneoplasia
FDA
FDA approves bosutinib for pediatric patients with chronic myelogenous leukemia
NatureRevClinOncol
NatureRevClinOncolYesterday, the FDA approved the BCR-ABL1 inhibitor b
#FDA
#CML
The Lancet Haematology
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the
The Lancet Haematology
The Lancet Haematology NEW online: results from the ph2 MASTER trial sugges
#mmsm
American Society of Clinical Oncology
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.